DE60223718D1 - Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen - Google Patents

Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen

Info

Publication number
DE60223718D1
DE60223718D1 DE60223718T DE60223718T DE60223718D1 DE 60223718 D1 DE60223718 D1 DE 60223718D1 DE 60223718 T DE60223718 T DE 60223718T DE 60223718 T DE60223718 T DE 60223718T DE 60223718 D1 DE60223718 D1 DE 60223718D1
Authority
DE
Germany
Prior art keywords
treatment
cognitive disorder
norepinephrine
recovery inhibitors
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60223718T
Other languages
English (en)
Other versions
DE60223718T2 (de
Inventor
Franklin Porter Bymaster
Donald Richard Gehlert
David Lee Mckinzie
Charles Renkin Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE60223718D1 publication Critical patent/DE60223718D1/de
Publication of DE60223718T2 publication Critical patent/DE60223718T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DE60223718T 2001-12-11 2002-11-27 Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen Expired - Fee Related DE60223718T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33917401P 2001-12-11 2001-12-11
US339174P 2001-12-11
PCT/US2002/036132 WO2003049724A1 (en) 2001-12-11 2002-11-27 Use of norepinephrine reuptake inhibitors for the treatment of cognitive failure

Publications (2)

Publication Number Publication Date
DE60223718D1 true DE60223718D1 (de) 2008-01-03
DE60223718T2 DE60223718T2 (de) 2008-10-30

Family

ID=23327833

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60223718T Expired - Fee Related DE60223718T2 (de) 2001-12-11 2002-11-27 Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen

Country Status (26)

Country Link
US (1) US20050009925A1 (de)
EP (1) EP1458368B1 (de)
JP (1) JP2005517647A (de)
KR (1) KR20040066895A (de)
CN (1) CN1713900A (de)
AU (1) AU2002352625A1 (de)
BR (1) BR0213581A (de)
CA (1) CA2467802A1 (de)
CO (1) CO5590907A2 (de)
CZ (1) CZ2004709A3 (de)
DE (1) DE60223718T2 (de)
EA (1) EA200400793A1 (de)
EC (1) ECSP045145A (de)
ES (1) ES2295435T3 (de)
HR (1) HRPK20040528B3 (de)
HU (1) HUP0402619A3 (de)
IL (1) IL161989A0 (de)
MX (1) MXPA04005716A (de)
MY (1) MY136367A (de)
NO (1) NO20042904L (de)
NZ (1) NZ532065A (de)
PL (1) PL369311A1 (de)
SK (1) SK2442004A3 (de)
TW (1) TW200300672A (de)
WO (1) WO2003049724A1 (de)
ZA (1) ZA200404274B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL373956A1 (en) * 2002-08-14 2005-09-19 Pharmacia & Upjohn Company Llc Use of reboxetine for the treatment of hot flashes
EP1708717B1 (de) * 2003-07-28 2011-10-05 Leslie Joe Dunaway Atomoxetin zur Behandlung von allergischer Rhinitis und Asthma
CA2530014A1 (en) * 2003-08-27 2005-03-10 Eli Lilly And Company Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
KR20060121178A (ko) * 2003-12-12 2006-11-28 일라이 릴리 앤드 캄파니 일과성 전신 열감, 충동 조절 장애 및 일반적인 의학상태로 인한 인격 변화 치료용 선택적 노르에피네프린재흡수 억제제
EP1745029A1 (de) * 2004-04-30 2007-01-24 Warner-Lambert Company LLC Substituierte morpholinverbindungen zur behandlung von erkrankungen des zentralen nervensystems
US7439399B2 (en) * 2004-06-28 2008-10-21 Teva Pharmaceutical Fine Chemicals Processes for the preparation of atomoxetine hydrochloride
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
US20100069389A1 (en) * 2008-09-06 2010-03-18 Bionevia Pharmaceuticals, Inc. Novel forms of reboxetine
US20100317731A1 (en) * 2009-06-12 2010-12-16 Shaya Elias K Hyperhidrosis treatment
TW201107485A (en) * 2009-07-31 2011-03-01 Univ Nat Taiwan Treating negative symptoms of schizophrenia associated with defective neuregulin 1 (NRG1)
JP6126531B2 (ja) * 2011-10-03 2017-05-10 国立研究開発法人国立長寿医療研究センター タウ凝集阻害剤
EP3610890A1 (de) 2012-11-14 2020-02-19 The Johns Hopkins University Verfahren und zusammensetzungen zur behandlung von schizophrenie
US9907799B2 (en) 2013-04-02 2018-03-06 The Doshisha Tau aggregation inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4314081A (en) * 1974-01-10 1982-02-02 Eli Lilly And Company Arloxyphenylpropylamines
US5281624A (en) * 1991-09-27 1994-01-25 Eli Lilly And Company N-alkyl-3-phenyl-3-(2-substituted phenoxy) propylamines and pharmaceutical use thereof
US5658590A (en) * 1995-01-11 1997-08-19 Eli Lilly And Company Treatment of attention-deficit/hyperactivity disorder
JP2003503450A (ja) * 1999-07-01 2003-01-28 ファルマシア・アンド・アップジョン・カンパニー 高選択的ノルエピネフリン再取込みインヒビターおよびその使用方法
BR0014733A (pt) * 1999-10-13 2002-06-11 Pfizer Prod Inc Derivados éter biarìlico úteis como inibidores de recaptação de monoamina
WO2002053104A2 (en) * 2001-01-02 2002-07-11 Sention, Inc. Use of catecholamine reuptake inhibitors to enhance memory
AU2002232470B2 (en) * 2001-01-02 2005-11-03 Pharmacia & Upjohn Company Llc New drug combinations of norepinehrine reuptake inhibitors and neuroleptic agents

Also Published As

Publication number Publication date
CO5590907A2 (es) 2005-12-30
DE60223718T2 (de) 2008-10-30
CZ2004709A3 (cs) 2004-10-13
KR20040066895A (ko) 2004-07-27
EP1458368A1 (de) 2004-09-22
HRP20040528A2 (en) 2004-10-31
WO2003049724A1 (en) 2003-06-19
ES2295435T3 (es) 2008-04-16
CN1713900A (zh) 2005-12-28
IL161989A0 (en) 2005-11-20
MY136367A (en) 2008-09-30
TW200300672A (en) 2003-06-16
CA2467802A1 (en) 2003-06-19
BR0213581A (pt) 2004-08-24
SK2442004A3 (en) 2004-12-01
AU2002352625A1 (en) 2003-06-23
NO20042904L (no) 2004-09-07
HRPK20040528B3 (en) 2006-03-31
ZA200404274B (en) 2005-09-13
MXPA04005716A (es) 2004-12-06
JP2005517647A (ja) 2005-06-16
US20050009925A1 (en) 2005-01-13
EA200400793A1 (ru) 2004-10-28
PL369311A1 (en) 2005-04-18
EP1458368B1 (de) 2007-11-21
ECSP045145A (es) 2004-07-23
HUP0402619A3 (en) 2008-04-28
HUP0402619A2 (hu) 2005-03-29
NZ532065A (en) 2007-03-30

Similar Documents

Publication Publication Date Title
DE602004023829D1 (de) Verfahren zur behandlung von sinuskopfschmerzen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE350375T1 (de) 17beta-hydroxysteroid dehydrogenase type 3 inhibitoren zur behandlung von androgen- abhängigen erkrankungen
NO20035610L (no) Fremgangsmate for behandling av vaeskeformig hydrokarbon
DE60325770D1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
DE60114580D1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE451921T1 (de) Phenylindole zur behandlung von hiv
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE296628T1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DE60208221D1 (de) Heterozyklische verbindungen zur behandlung von harnwegserkrankungen
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE346614T1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
DE60223718D1 (de) Verwendung von norepinephrin wiederaufnahmehemmern zur behandlung von kognitiven störungen
DE60218451D1 (de) 15-keto-prostaglandine zur behandlung arzneimittelinduzierter obstipation
DE60220043D1 (de) Carbamatverbindungen zur vorbeugung oder behandlung von neurodegenerativen störungen
DE60223688D1 (de) Verfahren zur behandlung von multiplem myelom
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE60238765D1 (de) Carbamatverbindungen zur behandlung von schmerz
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DE60214355D1 (de) Exemestan zur behandlung von hormonabhängigen störungen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE273276T1 (de) Cyclobutendion-derivate zur behandlung von artherosclerose
DE60331359D1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8339 Ceased/non-payment of the annual fee